Literature DB >> 12753753

Oral sustained delivery of paracetamol from in situ-gelling gellan and sodium alginate formulations.

Wataru Kubo1, Shozo Miyazaki, David Attwood.   

Abstract

The purpose of this study was to evaluate the potential for the oral sustained delivery of paracetamol of two formulations with in situ gelling properties. Oral administration of aqueous solutions of either gellan gum (1.0%, w/v) or sodium alginate (1.5%, w/v) containing calcium ions in complexed form resulted in the formation of gel depots in rabbit and rat stomachs as a consequence of the release of the calcium ions in the acidic environment. In vitro studies demonstrated diffusion-controlled release of paracetamol from the gels over a period of 6h. The bioavailability of paracetamol from the gels formed in situ in the stomachs of rabbits following oral administration of the liquid formulations was similar to that of a commercially available suspension containing an identical dose of paracetamol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753753     DOI: 10.1016/s0378-5173(03)00163-7

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  11 in total

1.  Development of Probiotic Formulations for Oral Candidiasis Prevention: Gellan Gum as a Carrier To Deliver Lactobacillus paracasei 28.4.

Authors:  Felipe de Camargo Ribeiro; Juliana Campos Junqueira; Jéssica Diane Dos Santos; Patrícia Pimentel de Barros; Rodnei Dennis Rossoni; Shashank Shukla; Beth Burgwyn Fuchs; Anita Shukla; Eleftherios Mylonakis
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

2.  Formulation and evaluation of in situ gelling systems for intranasal administration of gastrodin.

Authors:  Zheng Cai; Xiangrong Song; Feng Sun; Zhaoxiang Yang; Shixiang Hou; Zhongqiu Liu
Journal:  AAPS PharmSciTech       Date:  2011-08-31       Impact factor: 3.246

3.  A New Approach for Characterizing the Thixotropic Properties of Gel Formulations as Sprayable Agents Based on Rheological Analysis.

Authors:  Takayuki Terukina; Yoshiki Uchiyama; Fumiya Kikuma; Saki Fukumitsu; Nana Iwata; Takanori Kanazawa; Hiromu Kondo
Journal:  AAPS PharmSciTech       Date:  2022-04-21       Impact factor: 3.246

4.  In situ forming formulation: development, evaluation, and optimization using 3(3) factorial design.

Authors:  Ramesh C Nagarwal; A Srinatha; Jayanta K Pandit
Journal:  AAPS PharmSciTech       Date:  2009-07-28       Impact factor: 3.246

5.  Preparation, characterization and optimization of glipizide controlled release nanoparticles.

Authors:  J Emami; M S Shetab Boushehri; J Varshosaz
Journal:  Res Pharm Sci       Date:  2014 Sep-Oct

Review 6.  Polysaccharide Fabrication Platforms and Biocompatibility Assessment as Candidate Wound Dressing Materials.

Authors:  Donald C Aduba; Hu Yang
Journal:  Bioengineering (Basel)       Date:  2017-01-18

Review 7.  Recent Developments in Ion-Sensitive Systems for Pharmaceutical Applications.

Authors:  Michał Rudko; Tomasz Urbaniak; Witold Musiał
Journal:  Polymers (Basel)       Date:  2021-05-18       Impact factor: 4.329

Review 8.  Progress in the development of gelling agents for improved culturability of microorganisms.

Authors:  Nabajit Das; Naveen Tripathi; Srijoni Basu; Chandra Bose; Susmit Maitra; Sukant Khurana
Journal:  Front Microbiol       Date:  2015-07-23       Impact factor: 5.640

9.  Gelucire based in situ gelling emulsions: a potential carrier for sustained stomach specific delivery of gastric irritant drugs.

Authors:  Ashwin Saxena; Arun K Mishra; Navneet Verma; Shiv S Bhattacharya; Amitava Ghosh; Anurag Verma; Jayanta K Pandit
Journal:  Biomed Res Int       Date:  2013-11-10       Impact factor: 3.411

10.  Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl.

Authors:  Mohamed A El Nabarawi; Mahmoud H Teaima; Rehab A Abd El-Monem; Nagla A El Nabarawy; Dalia A Gaber
Journal:  Drug Des Devel Ther       Date:  2017-04-03       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.